1110006G06Rik Inhibitors
Chemical inhibitors of protein 1110006G06Rik can regulate its function by interfering with various signaling pathways and kinases that are essential for its activity. Staurosporine and dasatinib, for example, can inhibit a wide range of protein kinases that may phosphorylate protein 1110006G06Rik, leading to a decrease in its phosphorylation state and functional activity. Staurosporine is known for its broad-spectrum kinase inhibition, which means it can obstruct multiple kinases that could be involved in the phosphorylation and activation of protein 1110006G06Rik. Similarly, dasatinib can selectively inhibit Src family kinases and BCR-ABL, which are potentially involved in the phosphorylation events required for the proper functioning of protein 1110006G06Rik.
In addition to these broad kinase inhibitors, specific pathway inhibitors like LY294002 and wortmannin can prevent the activation of phosphoinositide 3-kinases (PI3K), which are upstream regulators of many signaling cascades. By blocking PI3K activity, these inhibitors can prevent the downstream signaling that may be necessary for protein 1110006G06Rik's function. Rapamycin, targeting the mTOR pathway, can also suppress the function of protein 1110006G06Rik by interfering with its required signaling pathways. Similarly, PD98059 and U0126 can inhibit the MEK/ERK pathway, which might be indispensable for protein 1110006G06Rik's activity. SP600125 and SB203580 can obstruct the JNK and p38 MAP kinase pathways, respectively, which could be involved in the functional regulation of protein 1110006G06Rik. Lastly, BAY 11-7082 and AG 490 can disrupt the NF-κB and JAK/STAT signaling pathways, respectively, which may be crucial for the activity of protein 1110006G06Rik, leading to its functional inhibition. These inhibitors together present a diverse arsenal for modulating the activity of protein 1110006G06Rik by targeting different kinases and signaling pathways that are potentially involved in its regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases. Since 1110006G06Rik could be phosphorylated by various kinases as part of its regulatory mechanism, staurosporine could inhibit those kinases, leading to a decrease in phosphorylation and thus functional inhibition of 1110006G06Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 could prevent the activation of downstream targets and signaling pathways that are essential for the functional activity of 1110006G06Rik, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that works by covalently binding to and inhibiting the enzyme. This inhibition could block downstream signaling that may be necessary for 1110006G06Rik function; thus, Wortmannin could functionally inhibit 1110006G06Rik by impeding necessary signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin selectively inhibits mTOR (mechanistic target of rapamycin). If 1110006G06Rik relies on mTOR signaling for its function, then rapamycin could functionally inhibit 1110006G06Rik by blocking this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). By inhibiting MEK, PD98059 could disrupt the MAPK/ERK pathway, which might be essential for the activity of 1110006G06Rik, thereby functionally inhibiting the protein. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is also a MEK inhibitor that prevents the activation of ERK. If the MAPK/ERK pathway is involved in the activity of 1110006G06Rik, the use of U0126 would lead to functional inhibition of 1110006G06Rik due to the blockade of this essential pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK could impair the JNK signaling pathway, which may be involved in the functional activity of 1110006G06Rik, resulting in its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By inhibiting p38 MAPK, SB203580 could disrupt signaling pathways that may be necessary for 1110006G06Rik activity, leading to its functional inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and BCR-ABL inhibitor. By inhibiting these kinases, Dasatinib could prevent phosphorylation of substrates involved in the functional activity of 1110006G06Rik, leading to its functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. If Src kinases are involved in the phosphorylation events needed for 1110006G06Rik activity, then inhibition by PP2 could lead to a decrease in 1110006G06Rik function. | ||||||